Xanodyne Pharmaceuticals, Inc. has received an approvable letter from the U.S. Food and Drug Administration (FDA) for Zipsor, its candidate for the treatment of patients with mild to moderate acute pain. Gregory Flexter, president and CEO of the Newport-based company, said Xanodyne has been informed that no additional clinical trials have been requested and said the company will work closely with the FDA to provide a complete response.
Newport
The Lane Report
- Greater Louisville March home sales down 5% from year ago
- School of Medicine, UofL Health create first-ever joint leadership role
- MSU Space Science programs expand reach and student opportunities
- New Ky Home initiative offers free marketing workshops to small business
- 18 UK faculty named 2025-26 University Research Professors
- Markey research team discovers gut hormone’s role in fatty liver disease
- OP-ED: State moving to speed up driver’s license system
- E & E Hardwoods to establish new operation in Bell County with $2.1M investment
- OpEd: Ky House leaders wisely insisted on 340B accountability
- Aegis Sortation to expand Louisville operation with nearly $16M investment
Add Comment